Tenderwize
Back to tender search

Open House Originale Rabattverträge 2025-08 - Roxadustat

Techniker Krankenkasse·Hamburg, Germany·Deadline Mar 30, 2027 · 221 days left·Open·Supplies
Sign up to saveOpen documents
Structured notice only
Original notice title

Germany – Pharmaceutical products – Open House Originale Rabattverträge 2025-08 - Roxadustat

50/100

Opportunity Score

Needs reviewLow complexity
SuppliesOpen
Why this score?

Opportunity

50 / 100

Complexity

20 / 100

Risk factors

Contract ends automatically at the end of the month when patent/market exclusivity expires, which could happen earlier...

No estimated value or guaranteed volume; revenue dependent on actual uptake.

Deep Portfolio Analysis

Deep Company Fit Analysis

Uses:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Overview

Moderate opportunity

Key Facts

  • Supplies contract
  • 1 lot
  • Duration until Mar 2027
  • Conclusion of rebate contracts under § 130c SGB V for the active ingredient Roxadustat.
  • Uniform contractual conditions, no individual negotiations.
Show full summary

Open House procedure for discount agreements on the active ingredient Roxadustat under German law (SGB V). Techniker Krankenkasse (lead buyer) and Handelskrankenkasse (non-lead) intend to conclude non-exclusive rebate contracts with all eligible pharmaceutical entrepreneurs. One lot, no estimated value provided. The procedure allows joining at any time during the contract term (max. 24 months). Submission is not via eProcurement but by email or post. The contract ends automatically upon patent expiry. No analyzed procurement documents beyond the notice.

Risks

Contract ends automatically at the end of the month when patent/market exclusivity expires, which could happen earlier...

No estimated value or guaranteed volume; revenue dependent on actual uptake.

Analysis may be incomplete

Only part of the procurement documentation was analyzed. Additional eligibility requirements, certificates, or submission documents may exist in the remaining tender documentation.

Key Requirements

Technical

  • Must be a pharmaceutical entrepreneur as per § 4(18) AMG with a valid marketing authorization for the drug.
  • Must have registered office in Germany, EU, or EEA.

Eligibility

  • Must declare no exclusion grounds under §§ 123, 124 GWB (criminal convictions, etc.).

Requirements may be incomplete.

Buyer

Location

Hamburg, DEU

Identifier

992-80116-93

Activity

Health

Lots (1)

LOT-0001

Open House Originale Rabattverträge 2025-08 - Roxadustat

Discount agreement for Roxadustat with uniform conditions; no exclusivity; maximum term from 01.04.2025 to 31.03.2027; early termination upon patent expiry.

SuppliesEU fundedElectronic submission

Location

DE600, Germany

Duration

Mar 2025 - Mar 2027

Category

Pharmaceutical products

Deadline

Deadline Mar 30, 2027

Procurement Details

Publication date
05 Mar 2025
Languages
German

Reference metadata

Legal basis
32014L0024

Reference IDs

Tender ID
147964-2025

Documents (1)

Procurement document 1

Similar tenders

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Belgium – Pharmaceutical products – Antimycotica

Aug 27

Denmark – Pharmaceutical products – Amgros 2027 1.1170.a

Sep 3

France – Pharmaceutical products – 26-10 : ACCORD-CADRE DE FOURNITURE DE MÉDICAMENTS 2026

Aug 21

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9